Biotech Values

[EYEBUYSTOX]

PPHM -

No boiler room, but the CEO will be presenting via webcast at the Wedbush conference on 8/15. If he reports, like he did last time he presented, that the MOS of the treatment arms in the ongoing 2nd line NSCLC trial have not yet been reached, that will put projected MOS at 12 months and counting vs. less than 6 for the control arm (which was reached in april) in the double blinded multi-center placebo controlled study phase IIb registrational study. You might want to listen and catch the next 500% run IMO.